Publications by authors named "H N Kaul"
Epidermis is one of the most rapidly proliferating tissues in the body with high demands for adenosine triphosphate and cellular building blocks. In this study, we show that to meet these requirements, keratinocytes constitutively express HIF-1α, even in the presence of oxygen levels sufficient for HIF-1α hydroxylation. We previously reported that mice with severe epidermal mitochondrial dysfunction actually showed a hyperproliferative epidermis but rapidly died of systemic lactic acidosis and hypoglycemia, indicating excessive glycolysis.
View Article and Find Full Text PDFArticle Synopsis
- Energy efficiency analysis of cropping systems reveals important insights into non-renewable energy dependence, particularly in facultative rainfed wheat varieties in Central Europe.
- The study found that winter wheat consistently outperformed spring wheat in energy efficiency across two growing seasons, with minimal impact from nitrogen fertilization.
- Optimal nitrogen fertilization for energy efficiency was identified at 72.0 kg N/ha, with zero nitrogen showing the best performance metrics for energy use efficiency and productivity.
Article Synopsis
- Current challenges in treating Hodgkin lymphoma (HL) include relapsed/refractory cases and long-term treatment toxicities, and genetic and TME analysis could improve risk assessment.
- This study used circulating tumor DNA sequencing from 243 patients to identify and validate three distinct HL subtypes: inflammatory immune escape, virally-driven, and oncogene-driven HL, each with unique characteristics.
- The findings suggest a noninvasive approach for personalized risk stratification and monitoring of minimal residual disease, which may help identify patients at high risk of relapse.*
Background: Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment of advanced-stage, classical Hodgkin lymphoma guided by PET after two cycles.
Methods: This randomised, multicentre, parallel, open-label, phase 3 trial was done in 233 trial sites across nine countries.